New COVID Shots Same As Old Ones
Two studies performed recently at Columbia University and Harvard University have found that the new COVID-19 bivalent (two-in-one) booster shots developed by Pfizer/BioNTech and Moderna/NIAID do not provide better protection against the BA.4 and BA.5 Omicron subvariant viruses than the original monovalent formulations of the shots.1 2 3 In the Columbia study, 19 people were […]
FDA Authorizes COVID Bivalent Shots for Children as Young as Five Years Old
On Oct. 12, 2022, the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) of the COVID bivalent booster versions of messenger RNA (mRNA) Comirnaty and Spikevax biologics developed by Pfizer/BioNTech and Moderna/NIAID for children as young as five or six years old, respectively. The FDA’s decision on Aug. 31 to grant […]
Safety and Effectiveness of New COVID Bivalent Boosters Based on a Study of Eight Mice?
With no safety and efficacy evidence from human clinical trials, on Aug. 31, 2022, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorizations (EUAs) for Pfizer/BioNTech’s Comirnaty and Moderna/NIAID’s Spikevax messenger RNA (mRNA) COVID-19 biologics to distribute “bivalent formulations” (two-in-one) of the shots to use as a “single booster dose.”1 2 The […]
Study: Natural Immunity Offers More Protection Than Three mRNA COVID Shots
As the debate continues surrounding the issue of bodily autonomy being violated by school and workplace COVID-19 vaccine mandates, a new research study that analyzed more than one million people has found that natural immunity to SARS-CoV-2 offers longer lasting protection than vaccination.1 The study, which was published in The New England Journal of Medicine […]
